Surfactant assisted rapid-release liposomal strategies
Dosage regimen enable BF211 to like a drug, providing a promising nano platform to deliver the cardiac glycosides and alleviate side effects
United States United Kingdom Netzsch Geraetebau Gmb Merck Darmstadt Jinyibai Biological Technology Co Laboratory Animals
Source: dovepress.com